Journal ArticleDOI
Phase II studies: which is worse, false positive or false negative?
Andre Rogatko,Samuel Litwin +1 more
About:
This article is published in Journal of the National Cancer Institute.The article was published on 1996-04-03. It has received 11 citations till now. The article focuses on the topics: False positive paradox & False Negative Reactions.read more
Citations
More filters
Journal ArticleDOI
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Steven J. Cohen,Linus Ho,Sulabha Ranganathan,James L. Abbruzzese,R. Katherine Alpaugh,Mary Beard,Nancy L. Lewis,Susan McLaughlin,Andre Rogatko,Juan J. Perez-Ruixo,Amanda M. Thistle,Tom Verhaeghe,Hao Wang,L. M. Weiner,John J. Wright,Gary R. Hudes,N. J. Meropol +16 more
TL;DR: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer.
Journal ArticleDOI
Content and Quality of Currently Published Phase II Cancer Trials
Luigi Mariani,Ettore Marubini +1 more
TL;DR: The quality of the statistical component of published phase II cancer trials is generally poor and raises suspicion that low quality is likely to bias study findings.
Journal ArticleDOI
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Anna C. Ferrari,Joshi J. Alumkal,Mark N. Stein,Mary-Ellen Taplin,James S. Babb,Ethan S Barnett,Alejandro Gomez-Pinillos,Xiaomei Liu,Dirk F. Moore,Robert S. DiPaola,Tomasz M. Beer +10 more
TL;DR: The 40 mg panobinostat/bicalutamide regimen increased rPF survival in CRPC patients resistant to 2ndLAARx and merits validation using a second-generation antiandrogen.
Journal ArticleDOI
Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
TL;DR: In view of the disappointing treatment results, gemcitabine using this particular dose regimen should not be considered for further investigation in patients with advanced hepatocellular carcinoma.
Journal ArticleDOI
Relapsing-remitting Multiple Sclerosis and Whole-Brain N-Acetylaspartate Measurement: Evidence for Different Clinical Cohorts—Initial Observations
Oded Gonen,David M. Moriarty,Belinda S.Y. Li,James S. Babb,Juan He,John Listerud,Dina A. Jacobs,Clyde E. Markowitz,Robert I. Grossman +8 more
TL;DR: Ascertaining an individual's NAA concentration dynamics might enable early forecast of disease course, reflect disease severity and thus influence treatment decisions, and improve clinical trial efficiency by allowing selection of candidates on the basis of WBNAA dynamics in addition to clinical status.
References
More filters
Journal ArticleDOI
Fever of unexplained origin: report on 100 cases.
Journal ArticleDOI
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
TL;DR: The limited diagnostic evaluation used in this study identified patients with treatable malignancies and increased the survival duration of a population of suspected UPT patients.